INIBIDORES DE CDK4/6 - ESTUDO EM COMBINAÇÃO COM LETROZOL., FULVESTRANTO, MANEJO DE EVENTOS ADVERSOS, TERAPIAS EMERGENTES (ADJ- POS NEOAJ COM DOENÇA RESIDUAL), EXTENSA REVISÃO ,INCLUSIVE MECANISMOS DE RESISTÊNCIA (Rb1MUTATIONS/pTEN )

INIBIDORES DE CDK4/6 - ESTUDO EM COMBINAÇÃO COM LETROZOL., FULVESTRANTO, MANEJO DE EVENTOS ADVERSOS, TERAPIAS EMERGENTES (ADJ- POS NEOAJ COM DOENÇA RESIDUAL), EXTENSA REVISÃO ,INCLUSIVE MECANISMOS DE RESISTÊNCIA (Rb1MUTATIONS/pTEN  ) 




















































Comentários

Postar um comentário

Postagens mais visitadas deste blog

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis

http://www.nature.com/articles/srep06269 Abstract Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR mutation in tissues has obvious limitations. Circulating free DNA (cfDNA) has been reported as an alternative approach for the detection of EGFR mutations. This systematic review and meta-analysis was designed to assess the diagnostic performance of cfDNA, compared with tissues. True-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) values were extracted or calculated for each study. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated. A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall diagnostic performance. 20 eligible studies involving 2012 cases were included in this m...
Leia mais

INIBIDORES DE CICLINA 4/6 RESISTÊNCIA / TRATAMENTO "BEYOND PROGRESSION " , EFETIVIDADE EM SNC (ABEMACICLIB) , PIORES PROGNÓSTICOS NOS PACIENTES COM METÁSTASES HEPÁTICAS

Imagem
INIBIDORES DE CICLINA 4/6     TRATAMENTO "BEYOND PROGRESSION " ,    EFETIVIDADE EM SNC (ABEMACICLIB) , PIORES PROGNÓSTICOS NOS PACIENTES COM METÁSTASES HEPÁTICAS ,  MECANISMOS DE RESISTÊNCIA  ‒ ( RB1 mutations were subclonal / New ESR1 and PIK3CA driver mutations acquired on both arms/    ESR1 Y537S selected by fulvestrant )
Leia mais